港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

496.720

-5.792-1.15%

漲家數：6

跌家數：25

平家數：2

市盈率：- -

高：507.303

開：502.573

低：495.158

收：502.512

成交量：8,175.03萬

成交額：18.06億

市值：3,152.73億

流通市值：2,806.09億

資料載入中...

總覽新聞資訊

恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理

北水動向|北水成交淨買入44.71億北水逢低加倉AI硬件股全天搶籌智譜(02513)超12億港元

歸創通橋(02190)9月14日斥資113.14萬港元回購5.5萬股

市場縮量調整，三大指數震盪回調，醫藥銀行集體護盤| 華寶基金3A日報（2026.9.14）

ETF日報(09.14)丨WCLC臨床數據密集兑現，創新藥板塊震盪回升算力需求預期遭重估

港股收評：恒指、國指終結5連跌！生物醫藥股狂歡，存儲芯片股承壓

艾普司韋破冰！AI製藥從概念照進現實，資本市場有何傾向？

港股收評：恒指漲0.45% 科指跌0.06% 創新藥概念股大漲存儲概念股下挫

大行評級丨傑富瑞：康方生物依沃西單抗H-2研究取得正面結果，維持「買入」評級

ETF風向標|創新藥板塊領升，港股創新藥ETF、恒生醫藥ETF和港股通醫藥ETF漲4%，短融ETF、科創50ETF上周「吸金」居前

小摩：康方生物(09926.HK)HARMONi-2總生存期數據強勁維持「增持」評級

新股前瞻|攻克抗生素耐藥性難題，普萊醫藥闖關港股能否獲市場下注？

港股異動 | 沛嘉醫療-B(09996)升逾3% GeminiOne®經導管緣對緣修復系統註冊申請獲國家藥監局批准

ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集機構看好創新藥投資機會

《大行》富瑞：康方生物(09926.HK)依沃西單抗單藥總生存期數據良好

阿斯达克财经

樂高科技、艾迪爾等35家藥企涉商業賄賂，登上貴州醫保基金失信企業「黑榜」

創新藥闖關醫保

国际金融报

A股異動 | 華大智造(688114.SH)升逾8% 虛擬細胞走向工程化落地公司聯手百圖生科綁定AI製藥下一代基礎設施

諾誠健華(09969)股價顯著上升14.18%，現價港幣$15.46

阿斯达克财经

港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化機構指回調後配置價值凸顯

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1574/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":496.71994,"timestamp":1789459707407,"preClose":502.51205,"halted":0,"volume":81750325,"delay":0,"changeRate":-0.011526,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-5.792114,"latestTime":"09-15 16:00:00","open":502.57327,"high":507.303,"low":495.15784,"amount":1806018702,"amplitude":0.024169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":3.744174,"peRate":166.585651,"turnoverRate":0.00304,"increases":7,"decrements":24,"flats":1,"marketCap":315273116400,"floatMarketCap":280608949080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":507.303,"amplitude":0.024169,"preClose":502.51205,"low":495.15784,"pbRate":"3.744174","latestPrice":496.71994,"volume":81750325,"delay":0,"open":502.57327,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":518.573,"twentyDayClose":502.603,"sixtyDayClose":431.958,"secType":"PLATE","market":"HK","turnoverRate":0.00304,"peRate":166.585651,"marketCap":315273116400,"floatMarketCap":280608949080,"timestamp":1789459707407,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667657738","title":"恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657738","media":"恒瑞医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657738?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:59","pubTimestamp":1789379940,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》，公司1类创新药、凝血因子XI单克隆抗体SHR-2004注射液的药品上市许可申请获受理，拟定适应症为：用于择期膝关节置换手术的成年患者，以预防静脉血栓形成。该研究旨在评价行择期TKA的患者使用SHR-2004注射液预防静脉血栓栓塞症的有效性和安全性。此外，SHR-2004用于卵巢癌术后VTE预防的Ⅱ期试验已完成。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-14/doc-iniruxuy4531842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","LNGR","159992","IPOS","06978","MEDX","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667652997","title":"北水動向|北水成交淨買入44.71億 北水逢低加倉AI硬件股 全天搶籌智譜(02513)超12億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667652997","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667652997?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:46","pubTimestamp":1789379185,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月14日港股市场，北水成交净买入44.71亿港元。北水净买入最多的个股是智谱、长飞光纤光缆、联想集团。港股通(沪)活跃成交股港股通(深)活跃成交股智谱获净买入12.01亿港元。浙商证券指出，该事件短期使AI硬件公司，大模型公司承压。康方生物、药明生物分别获净买入1.04亿、1385万港元。随新旗舰产品推出，该行认为小米收入及盈利应于2026年第三季见底，并于第四季开始反弹。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0128525689.USD","80992","LU0049112450.USD","LU0052756011.USD","LU0264606111.USD","LU0672654166.SGD","LU1961090484.USD","BK1506","AIPO","CHAT","LU0417516738.SGD","SG9999006597.SGD","BK1193","LU0048580855.USD","KURE","LU0561508036.HKD","02513","TCHI","LU0307460666.USD","BK1117","HK0000306685.HKD","HK0000320223.HKD","LU1206782309.USD","AGIX","LU0862451837.USD","LU0348735423.USD","00992","LU0634319403.HKD","LU0588546209.SGD","LU0972618739.USD","BK1574","IE00B0JY6N72.USD","LU1785774172.SGD","LU0310800965.SGD","IE00BPRC5H50.USD","LNVGY","06869","VTHR","ARTY","LU0890818403.SGD","QTOC","IE0034224299.USD","LU0348825331.USD","09926","LU1046422090.SGD","LU0029875118.USD","HK0000320264.USD","BK1161","HK0000306701.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667542416","title":"歸創通橋(02190)9月14日斥資113.14萬港元回購5.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667542416","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667542416?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:36","pubTimestamp":1789378589,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，该公司于2026年9月14日斥资113.14万港元回购5.5万股股份，每股回购价格为20.2-20.72港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02190","BK1583","BK1100","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654038","title":"市場縮量調整，三大指數震盪回調，醫藥銀行集體護盤| 華寶基金3A日報（2026.9.14）","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654038","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654038?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:30","pubTimestamp":1789378200,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-inirutpa4636245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1574","BK1161","161121","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667582651","title":"ETF日報(09.14)丨WCLC臨床數據密集兑現，創新藥板塊震盪回升 算力需求預期遭重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2667582651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667582651?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:44","pubTimestamp":1789375451,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，创新药板块震荡回升；AI巨头集体\"喊停\"，算力需求预期遭重估，通信板块多数走低。行业表现WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确，创新药板块震荡回升。消息面上，9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LNGR","MEDX","FDN","06978","BK4585","BK4550","EPAI","AIVC","BAI","159992","BK1161","AIQD","AIQU","IBBQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659490","title":"港股收評：恒指、國指終結5連跌！生物醫藥股狂歡，存儲芯片股承壓","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659490","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667659490?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:35","pubTimestamp":1789374958,"startTime":"0","endTime":"0","summary":"南向资金净买入44.71亿港元","market":"sg","thumbnail":"https://img3.gelonghui.com/442f4-225f5f62-62e8-4a54-8c80-004f29e3b51c.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/442f4-225f5f62-62e8-4a54-8c80-004f29e3b51c.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6643045","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0417516902.SGD","LU1048588211.SGD","SG9999014674.SGD","LU0762540952.USD","LU0856984785.SGD","83115","07200","07552","BK1615","IE0034224299.USD","03037","LU0456827905.SGD","HK0000306701.USD","LU0831093199.SGD","LU1188198961.HKD","03115","LU0228367735.SGD","LU1328615791.USD","BK1095","513600","LU0197773673.USD","LU0052750758.USD","BK1574","LU0315179316.USD","BIDU","LU1206782309.USD","LU0039217434.USD","LU2476274308.USD","LU0051755006.USD","LU1481107354.HKD","HK0000320264.USD","02802","09969","03423","LU0640798160.USD","LU0149721374.USD","HSTECH","LU0630378692.HKD","09067","HK0000306685.HKD","03033","03419","TCHI","LU1831875114.USD","LU0823426480.USD","BK1575","BK1587","LU0348735423.USD","03416","LU0348825331.USD","LU0229945570.USD","LU0173614495.USD","IE00B3M56506.USD","02828","LU1048596156.SGD","89888","LU0320764599.SGD","LU0417516738.SGD","BK1588","LU0072462343.USD","09088","SG9999002463.SGD","LU0871576103.HKD","02837","BK1161","LU0708995583.HKD","HSCEI","HHImain","LU1023057109.AUD","LU0630378429.USD","09888","LU0043850808.USD","LU0823426308.USD","07300","LU0244354667.USD","LU0463099449.HKD","LU1115378108.SGD","LU0307460666.USD","03088","02800","HK0000320223.HKD","BK1609","HSI","LU0163747925.USD","LU0164865239.USD","07226","LU0531971595.HKD","LU2778985437.USD","07500","LU0588546209.SGD","SG9999002828.SGD","03032","82800","LU0543330566.HKD","LU2039709279.SGD","02833","LU0762541174.USD","LU0287142896.SGD","LU0359202008.SGD","MCHmain","LU0821914370.USD","LU0197773160.USD","03417","09115","03067","LU0819121731.USD","LU0359201612.USD","07288","LU0326950275.SGD","82828","688428","07588","LU0164880469.USD","LU0359201885.HKD","LU0762542818.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665143","title":"艾普司韋破冰！AI製藥從概念照進現實，資本市場有何傾向？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665143","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665143?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:30","pubTimestamp":1789374601,"startTime":"0","endTime":"0","summary":"日前，国内首款AI辅助研发的原创药艾普司韦获批上市。比如，艾普司韦，从源头发现到完成临床试验，仅用时三年半。而艾普司韦的研发过程，充分展现了AI技术对新药研发的颠覆性赋能。三重核心共振实际上，国内AI制药已从早期的概念探索、技术试错阶段，正式迈入商业化落地爆发期。除艾普司韦外，国内多家药企、科创企业布局的AI辅助研发新药已进入临床试验阶段，覆盖抗感染、抗肿瘤、慢性病、罕见病等多个热门领域。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/14/20260914530026.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/14/20260914530026.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260914/32369044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","VTHR","ARTY","CHAT","BK1574","AIPO","AGIX","QTOC","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667593836","title":"港股收評：恒指漲0.45% 科指跌0.06% 創新藥概念股大漲 存儲概念股下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2667593836","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667593836?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:08","pubTimestamp":1789373280,"startTime":"0","endTime":"0","summary":"截至收盘，恒生指数涨0.45%，报24917.60，恒生科技指数跌0.06%，国企指数涨0.46%。盘面上，科网股涨跌不一，快手跌超2%，阿里跌超1%，小米涨超3%，联想涨超2%；创新药概念股大涨，诺诚健华涨超14%；汽车股活跃，北京汽车涨超17%；存储概念股跌幅居前，江波龙跌超9%。创新药概念股大涨，诺诚健华涨超14%。广汽集团A股因“重要事项未公告”于9月14日全天紧急停牌。存储概念股跌幅居前，江波龙跌超9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-14/doc-inirutny4042987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4505","BK4533","03037","01958","LU0918141887.USD","BK1119","LU0039217434.USD","BK4588","LU1688375341.USD","07200","BK1575","LU1366334578.USD","LU0072462343.USD","07226","LU1235295612.USD","BK1583","82800","LU0048580855.USD","01951","LU0106959298.USD","513600","LU1366334651.USD","LU1880383440.USD","LU2778985437.USD","LU1303224171.USD","LU2294711473.HKD","BABU","LU0791591158.USD","ONLN","LU0823426308.USD","LU1008478684.HKD","BK1539","LU0605514214.HKD","BK4503","LU0791590937.USD","LU0540923850.HKD","LU0588546209.SGD","LU1769817179.HKD","LU1813983027.USD","BBYY","LU1823568750.SGD","BK1161","LU1868838027.USD","02837","IE00BF5LJ272.USD","LU0254981946.USD","LU0348766576.USD","LU0821914370.USD","BK4579","09969","LU1719994722.HKD","81810","BK1193","03033","BK4554","LU0047713382.USD","LU1152091168.USD","LU0545039389.USD","LU0143863198.USD","BK4527","LU0264606111.USD","LU2257852520.SGD","BK1610","LU2097828631.EUR","LU0049112450.USD","03067","LU0084288322.USD","BK1219","LU0345775950.USD","LU2039709279.SGD","BK4581","LU0463099449.HKD","LU0326950275.SGD","LU0449515922.USD","BK1502","LU0531971595.HKD","LU0128522157.USD","LU1769817096.USD","BK4585","LU0417516738.SGD","LU0972618739.USD","LU1046422090.SGD","LU0456846285.SGD","LU0651946864.USD","LU0235996351.USD","LU0572944931.SGD","07552","LU0359201612.USD","LU0348816934.USD","LU1770036033.HKD","LU1051769294.HKD","BK1591","LU0348735423.USD","LU0499858438.USD","02238","LU0543330483.HKD","LU0672654166.SGD","BK4531","LU0251143458.SGD","LU0823413587.USD","LU1808992512.USD","LU0823038988.USD","HK0000306701.USD","LU1023057109.AUD","KSTmain","LU0634319403.HKD","09088","03423","SOCL","LU2148611432.USD","LU1720050803.USD","LU0572940350.SGD","SG9999003461.SGD","BK4526","LU0949170772.SGD","LU0651947912.USD","LU2097828805.USD","LU0128525689.USD","LU0370786039.SGD","LU0149721374.USD","BK1608","LU0553294199.USD","LU1481107354.HKD","LU0348825331.USD","LU1961090484.USD","LU0169518387.USD","LU2087589342.USD","DRAG","03419","LNVGY","LU0449509016.USD","HK0000165453.HKD","LU0320764755.SGD","LU1956131251.USD","BK4535","01024","LU0307460666.USD","HK0000320223.HKD","LU0210526637.USD","LU0067412154.USD","LU0417516902.SGD","LU0531970944.HKD","LU1152091754.HKD","LU0327786744.USD","IE00B0JY6N72.USD","BK4614","LU1242518931.SGD","LU1328277881.USD","LU1242518857.USD","LU0348814723.USD","LU0164872284.USD","LU1282648689.USD","LU0348767384.USD","LU0650527681.SGD","BK4543","XIACY","02833","03417","LU0661504455.SGD","LU0862451753.SGD","LU0029875118.USD","BK4565","LU0051755006.USD","HHImain","LU0054450605.USD","LU0320764599.SGD","LU1770034418.SGD","DRGN","TCHI","LU0456842615.SGD","LU0328353924.USD","BK1095","BK4502","LU0072913022.USD","LU0164865239.USD","LU0499858602.USD","BK1523","HK0000320264.USD","LU2097828557.USD","BABX","09067","LU0594300419.USD","MCHmain","LU0572939691.SGD","LU0880133367.SGD","LU2226246903.HKD","07300","BK4122","BK4220","80992","LU0593848301.USD","LU0675040207.SGD","SG9999001093.SGD","81024","LU1981816686.USD","LU0140636845.USD","83115","LU1048596156.SGD","IE00B3M56506.USD","LU0052750758.USD","HSI","ALBmain","LU0823039010.USD","LU1868837565.USD","LU0890818403.SGD","LU1048588211.SGD","IE0003895053.USD","09988","IE00BFMHRM44.USD","LU0214875030.USD","02800","LU1105468828.SGD","00992","LU1794554557.SGD","LU0310800965.SGD","LU0823413660.USD","LU0823041008.USD","CLIX","BABW","01810","601238","LU0708995583.HKD","HXXD.SI","03032","LU0211977185.USD","KBAB","LU2476274720.SGD","03088","09115","MIUmain","IE0034224299.USD","LU2097828714.EUR","BK1589","BK1597","LU1267930227.SGD","BK4587","LU1003077747.HKD","LU0143863784.USD","BABO","LU0345776255.USD","LU2097828474.EUR","LU0823426480.USD","LU1235294995.USD","LU0052756011.USD","HSTECH","07500","LU0738911758.USD","LU0918141705.HKD","LU0164880469.USD","LU2152927971.USD","LU1880383366.USD","LU0862451837.USD","LU0823397285.USD","LU0979878070.USD","BK4607","LU0244354667.USD","BK1590","LU0700851271.USD","LU0594300179.USD","LU0359202008.SGD","BK4534","LU0871576103.HKD","BK4524","BK1607","BK1506","BK4558","LU2242644610.SGD","LU2476274308.USD","BK1521","BK4575","LU0611395673.USD","LU1046421795.USD","SG9999002463.SGD","LU0359201885.HKD","BK1574","IE0032431581.USD","LU0823040885.USD","LU1323998911.USD","LU1251922891.USD","BK1526","LU0348827113.USD","HK0000306685.HKD","BK1618","LU0823397103.USD","BK1615","BABC","LU0441854154.USD","LU1515016050.SGD","LU0231483743.USD","LU0314109678.HKD","LU0797268264.HKD","LU1051768304.USD","LU1188198961.HKD","BABA","BK4504","LU0117841782.USD","688428","BK4548","LU0501845795.SGD","LU2399975544.HKD","HK0000286598.CNH","LU0561508036.HKD","BK4538","LU1785774172.SGD","LU0456827905.SGD","03115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656624","title":"大行評級丨傑富瑞：康方生物依沃西單抗H-2研究取得正面結果，維持「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656624","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656624?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:59","pubTimestamp":1789372758,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1720050803.USD","IE00B5MMRT66.SGD","LU1961090484.USD","LU2476274720.SGD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348766576.USD","LU0348783233.USD","LU2476274308.USD","LU0561508036.HKD","LU0348735423.USD","LU0348784397.USD","LU0634319403.HKD","LU0348827113.USD","KURE","LU2399975544.HKD","09926","BK1161","LU0417516571.SGD","BK1574","LU0348767384.USD","LU2488822045.USD","LU0540923850.HKD","LU2778985437.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0417516738.SGD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656312","title":"ETF風向標|創新藥板塊領升，港股創新藥ETF、恒生醫藥ETF和港股通醫藥ETF漲4%，短融ETF、科創50ETF上周「吸金」居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656312","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656312?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:48","pubTimestamp":1789372094,"startTime":"0","endTime":"0","summary":"8张图速览","market":"sh","thumbnail":"https://img3.gelonghui.com/c22ef-7f006f6d-0c57-40d1-bf4f-5bf2a2ea4eca.jpg?guru_height=2160&guru_width=4096&guru_size=709194","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/c22ef-7f006f6d-0c57-40d1-bf4f-5bf2a2ea4eca.jpg?guru_height=2160&guru_width=4096&guru_size=709194"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6641832","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_fund_highlight","symbols":["159992","159929","159316","06978","BK1574","BK1161","159681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656089","title":"小摩：康方生物(09926.HK)HARMONi-2總生存期數據強勁 維持「增持」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656089?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:38","pubTimestamp":1789371481,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348827113.USD","IE00B5MMRT66.SGD","LU2488822045.USD","09926","LU1794554557.SGD","LU0348783233.USD","LU2778985437.USD","IE00B543WZ88.USD","KURE","LU2399975544.HKD","LU0634319403.HKD","LU0417516902.SGD","LU0561508036.HKD","LU0348735423.USD","LU0348784397.USD","LU0348825331.USD","LU1720050803.USD","BK1574","BK1161","LU0417516738.SGD","LU0540923850.HKD","LU2476274720.SGD","LU0348767384.USD","LU0348766576.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU0417516571.SGD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667765505","title":"新股前瞻|攻克抗生素耐藥性難題，普萊醫藥闖關港股能否獲市場下注？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667765505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667765505?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:36","pubTimestamp":1789371362,"startTime":"0","endTime":"0","summary":"近日，普莱医药向港交所主板递交上市申请，中信证券担任独家保荐人，这是公司继2月13日首次提交上市申请后的第二次递表。目前的治疗药物以唑类抗真菌药为主，但耐药性问题同样存在。目前该产品正在中国进行一项II期临床试验，且已获FDA批准在美国进行一项II期临床试验。整体来看，在全球抗生素耐药性问题日益严峻的背景下，抗菌肽作为新型抗感染药物具备广阔的市场前景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1515","KCAI","BK1161","BK1574","BK4588","159938","BK4585","09939"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2667563655","title":"港股異動 | 沛嘉醫療-B(09996)升逾3% GeminiOne®經導管緣對緣修復系統註冊申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667563655","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667563655?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:18","pubTimestamp":1789370281,"startTime":"0","endTime":"0","summary":"消息面上，9月11日，沛嘉医疗-B发布公告，公司自主研发的GeminiOne经导管缘对缘修复系统近期已获中华人民共和国国家药品监督管理局批准其注册申请。GeminiOne获批标志着集团正式进入二尖瓣反流的商业化治疗领域，并代表集团在主动脉瓣狭窄及主动脉瓣反流治疗既有布局的基础上，进一步显著扩充其经导管瓣膜治疗产品组合。GeminiOne之EU MDR CE标志注册申请已提交，而美国早期可行性研究现正进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK4588","KCAI","BK1583","BK4585","BK1100","VXUS","BK1574","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667554366","title":"ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集 機構看好創新藥投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554366","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554366?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华夏恒生生科涨超4%。截至发稿，涨4.01%，报15.58港元，成交额6924.78万港元。本次WCLC会议上，中国新药表现亮眼，入选口头报告研究19项，小型口头报告研究45项，刷新记录。国金证券称，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03069","LNGR","IBBQ","BK4588","FDN","06978","BK1574","BK4550","159992","BK1161","MEDX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655595","title":"《大行》富瑞：康方生物(09926.HK)依沃西單抗單藥總生存期數據良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655595","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667655595?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:06","pubTimestamp":1789369560,"startTime":"0","endTime":"0","summary":"富瑞发表研究报告指，康方生物(09926.HK) 依沃西单抗(Ivonescimab)H-2研究取得正面结果，数据显示，其中期总生存期(OS)具统计学显著性，单药一线治疗PD-L1阳性非小细胞肺癌较帕博利珠单抗(Pembrolizumab)OS显著延长，OS中位数为30.8个月，风险比为0.73，中位随访36个月，对比帕博利珠单抗OS中位数为22.6个月。富瑞指出，康方生物依沃西单抗拥有总生存期优势，数据令人鼓舞，维持“买入”评级及目标价226元。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-14 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200424093930528_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200424093930528_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544311/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544311/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","09926","LU0348827113.USD","LU0417516571.SGD","LU0561508036.HKD","BK1161","LU0348783233.USD","BK1574","LU2399975544.HKD","KURE","LU1720050803.USD","LU2476274720.SGD","LU0348825331.USD","LU0634319403.HKD","LU1961090484.USD","LU0348766576.USD","LU0348735423.USD","LU1794554557.SGD","LU2476274308.USD","LU0348784397.USD","LU2778985437.USD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU0348767384.USD","IE00BPRC5H50.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667536746","title":"樂高科技、艾迪爾等35家藥企涉商業賄賂，登上貴州醫保基金失信企業「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2667536746","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667536746?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:51","pubTimestamp":1789368717,"startTime":"0","endTime":"0","summary":"根据公告，对于配送企业，根据信用评价结果限制或中止配送企业在贵州省的配送资格1-5年；对于生产企业，除提醒告诫、提示风险外，限制或中止相关涉案产品或全部产品挂网、投标资格。据悉，贵州省医保基金运行服务中心给出了修复信用评级的方法。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789368658648386760","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["AGNG","BK1583","GDOC","BK1574","LNGR","MEDX","09996","IEIH","PTH","HART","MDEV","LGHT","BK1100","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653941","title":"創新藥闖關醫保","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653941","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653941?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:46","pubTimestamp":1789368365,"startTime":"0","endTime":"0","summary":"张力制图9月5日至8日，2026年国家基本医保药品目录现场谈判（下称“国谈”）竞价工作在北京开展，上百家国内外药企代表到场参与。本次共有124个目录外药品入围谈判竞价环节，肿瘤、罕见病、慢性病、儿童用药等社会关注度较高的创新药均在列，有望通过谈判纳入新版国家医保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873368645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873368645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","MEDX","LNGR","159992","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667588066","title":"A股異動 | 華大智造(688114.SH)升逾8% 虛擬細胞走向工程化落地 公司聯手百圖生科綁定AI製藥下一代基礎設施","url":"https://stock-news.laohu8.com/highlight/detail?id=2667588066","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667588066?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:02","pubTimestamp":1789365758,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华大智造午后涨超8%，截至发稿，涨7.36%，报58.37元，成交额3.81亿元。消息面上，9月11日，全栈生命科学工具全球提供商华大智造与生命科学基础大模型全球领跑者百图生科达成战略合作：双方将面向具体客户和研发场景，共建专属细胞大模型，并以此为底座，开发面向虚拟细胞、虚拟扰动的专属高质量数据产出基础设施。AI4S基座龙头与AI4S头部大模型的联手，落点是行业最稀缺的高质量数据产能。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02827","BK0251","BK1191","03130","BK1574","CHAT","ARTY","83130","02846","QTOC","159982","AIPO","01477","07233","399300","AGIX","688114","VTHR","BK1147","03188","83188","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667302276","title":"諾誠健華(09969)股價顯著上升14.18%，現價港幣$15.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2667302276","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667302276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:45","pubTimestamp":1789364700,"startTime":"0","endTime":"0","summary":"[上升股]诺诚健华(09969) 股价在下午01:44比前收市价显著上升14.18%，现股价为港币$15.46。至目前为止，今日最高价为$15.46，而最低价为$13.38。总成交量为1.261千万股，总成交金额为港币$1.864亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141428/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141428/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["688428","BK1574","BK0239","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0561508036.HKD","KCAI","LU0634319403.HKD","06978","LU1961090484.USD","IBBQ","KURE","159992","BK4588","LU0348767384.USD","01177","LU0348735423.USD","LU0455707207.USD","LU2476274308.USD","LU0607220059.USD","BK1593","LU0348784397.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0417516738.SGD","01801","LU2097828805.USD","LU2097828714.EUR","HK0000165453.HKD","LU0348827113.USD","MEDX","LU2476274720.SGD","09969","LNGR","LU1831875114.USD","09926","LU0244354667.USD","LU1188198961.HKD","LU0348825331.USD","LU2097828557.USD","BK1574","LU0326950275.SGD","LU1969619763.USD","BK1191","LU0348766576.USD","01530","BK1161","IE00BZ08YR35.GBP","BK1521","LU2242644610.SGD","LU2778985437.USD","BK1589","VXUS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":3,"totalSize":348,"code":"91000000","status":"200"}]}}